A share price of Amylyx Pharmaceuticals Inc [AMLX] is currently trading at $14.12, down -0.98%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AMLX shares have gain 11.27% over the last week, with a monthly amount glided 21.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on June 24, 2025, and set its price target to $17. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $12 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Mizuho upgraded its rating to a Outperform but $7 remained the price target by the analyst firm on April 07, 2025. Robert W. Baird upgraded its rating to Outperform for this stock on November 18, 2024, and upped its price target to $11. In a note dated October 23, 2024, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $4.20 to $10.
Amylyx Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $2.60 and $15.16. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $14.12 at the most recent close of the market. An investor can expect a potential return of 23.94% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
Trailing Twelve Months sales for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] were -0.25M which represents 100.00% growth. Gross Profit Margin for this corporation currently stands at 5.46% with Operating Profit Margin at 791.06%, Pretax Profit Margin comes in at 755.96%, and Net Profit Margin reading is 753.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.96, Equity is -1.03 and Total Capital is -1.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] is 8.72. As well, the Quick Ratio is 8.72, while the Cash Ratio is 2.71.
Transactions by insiders
Recent insider trading involved Klee Justin B., Co-Chief Executive Officer, that happened on Sep 30 ’25 when 29975.0 shares were sold. Chief Legal Officer, Mazzariello Gina completed a deal on Sep 30 ’25 to sell 8828.0 shares. Meanwhile, Chief Financial Officer FRATES JAMES M sold 10558.0 shares on Sep 30 ’25.
